Sakaguchi Masakuni, Maebayashi Toshiya, Aizawa Takuya, Ishibashi Naoya, Saito Tsutomu
Department of Radiology, Nihon University School of Medicine, Tokyo, Japan
Department of Radiology, Nihon University School of Medicine, Tokyo, Japan.
Anticancer Res. 2016 Oct;36(10):5519-5525. doi: 10.21873/anticanres.11134.
To evaluate clinical outcomes of three-dimensional conformal radiotherapy (3D-CRT) alone in patients with bladder cancer who were unfit for concurrent standard chemotherapy.
Between January 2007 and May 2016, 34 patients (20 men, 14 women) aged 65-97 years (median=83) with bladder cancer cT1-4bN0-1M1 were treated with conformal whole-bladder radiotherapy with fractions of 1.8-3 Gy up to a total dose of 40-50 Gy.
Median survival was 10 months (range=1-99); 1-year and 3-year survival was 51.4% and 34.3%, respectively. Radiation dose >50 Gy was associated with improved survival. Three-year local control (LC) rate was 58.8%. On multivariate analysis, only radiation dose showed a significant association with LC.
Our results demonstrated the safety and feasibility of radiotherapy in patients with bladder cancer unfit for concurrent standard chemotherapy. A higher radiation dose may confer superior LC and overall survival (OS) without complications.
评估单纯三维适形放疗（3D-CRT）用于不适合同步标准化疗的膀胱癌患者的临床疗效。
2007年1月至2016年5月，34例年龄65 - 97岁（中位年龄 = 83岁）的膀胱癌cT1 - 4bN0 - 1M1患者接受了适形全膀胱放疗，每次分割剂量为1.8 - 3 Gy，总剂量达40 - 50 Gy。
中位生存期为10个月（范围 = 1 - 99个月）；1年和3年生存率分别为51.4%和34.3%。放疗剂量>50 Gy与生存率提高相关。三年局部控制（LC）率为58.8%。多因素分析显示，仅放疗剂量与局部控制有显著关联。
我们的结果证明了放疗用于不适合同步标准化疗的膀胱癌患者的安全性和可行性。较高的放疗剂量可能带来更好的局部控制和总生存期（OS）且无并发症。
